trending Market Intelligence /marketintelligence/en/news-insights/trending/orGbkUhi5kYT6nFtscf5WQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Arch Therapeutics wound gel gets US FDA clearance

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Arch Therapeutics wound gel gets US FDA clearance

Arch Therapeutics Inc. said the U.S. Food and Drug Administration granted 510(k) clearance to its AC5 topical gel for wound management.

The topical dressing is indicated to manage partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers and surgical wounds.

Arch Therapeutics had resubmitted its application seeking approval for AC5 topical gel. The biotechnology company said it would delay the product's commercialization until the first half of 2019.

Framingham, Mass.-based Arch Therapeutics uses a self-assembling barrier technology platform to develop approaches to stop bleeding, control leaking and manage wounds during surgery, trauma and interventional care.